Sprycel
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL
December 17, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Sprycel, all
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
NICE recommends two Novartis cancer treatments
December 6, 2011Sales and Marketing Glivec, Novartis, Sprycel, Tasigna
Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …
New discount persuades NICE to back Novartis’ Tasigna
August 18, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …
‘Weak’ evidence leads to NICE no for three leukaemia drugs
May 6, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …
